RNA

Atrium Therapeutics, Inc

• PUBT·06/23 20:05

  Atrium Therapeutics grants 8 new hires stock awards including 66,000 options at $12.66

• PR Newswire·06/23 20:05

  Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

• Dow Jones·06/18 13:00

  Avidity Biosciences Initiated at Overweight by Cantor Fitzgerald

• Dow Jones·06/18 13:00

  Avidity Biosciences Price Target Announced at $25.00/Share by Cantor Fitzgerald

• TipRanks·06/18 10:12

  Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

• Dow Jones·05/15 17:43

  Avidity Biosciences Initiated at Outperform by Leerink Partners

• Dow Jones·05/15 17:43

  Avidity Biosciences Price Target Announced at $25.00/Share by Leerink Partners

• TipRanks·05/15 16:48

  Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

• Seeking Alpha·05/15 13:31

  Atrium Therapeutics, Inc. reports Q1 results

• TipRanks·05/15 10:21

  Atrium Therapeutics initiated with an Outperform at Leerink

• Reuters·05/15 10:07

  ATRIUM THERAPEUTICS INC <RNA.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $25

• Reuters·05/14 20:50

  Atrium Therapeutics Q1 collaboration revenue surges after spin-off

• Dow Jones·05/14 20:43

  *Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA

• Dow Jones·05/14 20:43

  *Atrium Therapeutics 1Q Rev $19.6M >RNA

• Dow Jones·05/14 20:40

  *Atrium Therapeutics 1Q Loss/Shr 97c >RNA